Can a new daily pill quiet the immune attack behind psoriasis?

NCT ID NCT07724366

Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This phase 3 trial is testing an experimental daily capsule called TQH3906 in adults with moderate to severe plaque psoriasis. The drug works by blocking a key immune pathway involved in skin inflammation. Researchers are comparing TQH3906 against a placebo and an approved treatment to see if it can safely clear skin plaques and improve quality of life over 52 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: an experimental TYK2 inhibitor called TQH3906, taken as a daily capsule
What this could lead to: If it works, TQH3906 could offer a new once-daily oral option for people with moderate to severe plaque psoriasis, potentially clearing skin plaques and improving quality of life.
What could go wrong: This is an early-phase 3 trial, so the drug's effectiveness and safety are not yet proven. Possible side effects include immune suppression and infections, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:1. Participants must be between 18 and 75 years old when signing the informed consent form (ICF), regardless of gender; 2. Confirmed diagnosis of plaque psoriasis for at least 6 months at screenin 3. Disease is stable at screening and baseline visits, and the following criteria are met: * Static Physician Global Assessment (sPGA) score ≥3; * Psoriasis Area and Severity Index (PASI) score ≥12; * Body Surface Area (BSA) affected by psoriasis ≥10%; 4. Deemed by the Investigator as suitable for systemic therapy or phototherapy; 5. Women of childbearing potential must have a negative pregnancy test at screening and baseline visits. Women of childbearing potential and male trial participants whose spouse or partner is a woman of childbearing potential must be willing to use at least one effective method of contraception as specified in the protocol during the study period (from signing the ICF until 30 days after the last dose of investigational drug). Male trial participants must also commit to not donating sperm during the study period and within 30 days after the last dose of study drug; 6. Before initiating any screening or study-specific procedures, trial participants must be able to understand and willing to comply with all protocol requirements, and voluntarily sign and date the ICF. Exclusion Criteria:1.Presence of non-plaque psoriasis during the Screening period or at the Baseline visit; 2.Past or current diagnosis of drug-induced psoriasis; 3.Concomitant other autoimmune diseases, including but not limited to rheumatoid arthritis, sarcoidosis, and systemic lupus erythematosus; 4.Receiving therapeutic agents for psoriatic arthritis (PsA) other than stable-dose non-steroidal anti-inflammatory drugs (NSAIDs) or analgesics. 5.Prior exposure to TQH3906 Capsules or Deucravacitinib Tablets; 6.Receipt of any of the following medications or treatments within the specified time window: 1. Any topical agents or treatments that may interfere with psoriasis assessment, administered within 2 weeks before the Baseline visit; 2. Psoriasis phototherapy administered within 4 weeks before the Baseline visit; 3. Any biologics or biosimilars thereof, administered within the specified time frame before the Baseline visit; 4. Systemic non-biologic psoriasis therapy and/or systemic immunosuppressive treatment administered within 4 weeks before the Baseline visit; 5) Within 6 months prior to the baseline visit: Leflunomide; 6) Within 4 weeks prior to the baseline visit: Traditional Chinese medicines (TCM), Chinese proprietary medicines, or herbal preparations used for psoriasis treatment or with unknown composition/nature, including but not limited to Total Glucosides of Paeony, Tripterygium wilfordii preparations, Compound Glycyrrhizin preparations, Compound Qingdai preparations, etc.; 7) Within 4 weeks prior to the baseline visit: Any live vaccines or live-attenuated vaccines; OR anticipated need to receive live vaccines or live-attenuated vaccines during the study period including at least 4 weeks after the last dose of investigational product; 8) Within 3 months prior to the baseline visit (or 5 half-lives, whichever is longer): Investigational biological agent treatment; OR within 30 days prior to the baseline visit (or 5 half-lives, whichever is longer): Any other investigational drug treatment; OR currently participating in other clinical trials; 7. Active infection/history of infection, or receipt of specific anti-infective therapies within the specified time windows; 8. Previous or current presence of severe or unstable diseases or medical conditions involving neurological, cardiovascular, respiratory, digestive, urinary, hematological, or immune systems that, in the Investigator's judgment, may interfere with outcome assessment or affect participation safety 9. Laboratory test abnormalities meeting any of the following criteria during the screening period: 1) Hemoglobin \<90.0 g/L; 2) White blood cell count \<3.0×10⁹/L; 3) Neutrophil count \<1.0×10⁹/L; 4) Lymphocyte count \<0.5×10⁹/L; 5) Platelet count \<100×10⁹/L; 6) Alanine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) \>3× Upper Limit of Normal (ULN); 7) Total bilirubin (TBIL) \>1.5× ULN; 8) Estimated creatinine clearance \<45 mL/min calculated based on the Cockcroft-Gault formula. (See Appendix 2 for calculation formula); 9) Thyroid-stimulating hormone (TSH) outside the normal reference range, concomitant with free T4 or T3 also outside the normal reference range. 10\. History of drug or alcohol abuse within 6 months prior to screening; 11. Known allergy, hypersensitivity, or intolerance to TQH3906 capsules, deucravacitinib tablets, or any excipient ingredients; 12. Women who are pregnant, breastfeeding, or planning to become pregnant during the trial, and men who plan to father children or donate sperm during the trial; 13. Trial participants who are employees of the Sponsor, third-party agency staff, or direct research center staff involved in this study or their family members; 14. Per Investigator assessment, presence of any other medical, psychiatric, or other reasons that render the trial participant unsuitable for participation in this study. \-

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

43 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

Affiliated Hospital of Chengde Medical University
RECRUITING

Chengde, Hebei, 067000, China
Affiliated Hospital of Inner Mongolia Medical University
NOT_YET_RECRUITING

Hohhot, Inner Mongolia, 10010, China
Affiliated Hospital of Jiangsu University
RECRUITING

Zhenjiang, Jiangsu, 212008, China
Central Hospital Affiliated to Shenyang Medical College
NOT_YET_RECRUITING

Shenyang, Liaoning, 110023, China
Chinese Academy of Medical Sciences Hospital for Skin Diseases
WITHDRAWN

Nanjing, Jiangsu, 210042, China
Chongqing Traditional Chinese Medicine Hospital
NOT_YET_RECRUITING

Chongqing, Chongqing Municipality, 400011, China
Dermatology Hospital of Southern Medical University
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510000, China
Gerneral Hospital of Ningxia Medical Univercity
NOT_YET_RECRUITING

Yinchuan, The Ningxia Hui Autonomous Region, 750000, China
Guangdong Provincial People's Hospital
NOT_YET_RECRUITING

Guangzhou, Guangdong, 519041, China
Guizhou Provincial People's Hospital
NOT_YET_RECRUITING

Guiyang, Guizhou, 550002, China
Hainan Fifth People's Hospital
NOT_YET_RECRUITING

Haikou, Hainan, 570100, China
Heilongjiang Provincial Hospital
RECRUITING

Harbin, Heilongjiang, 150036, China
Huashan Hospital, Fudan University
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200040, China
Jiaxing First Hospital
NOT_YET_RECRUITING

Jiaxing, Zhejiang, 314001, China
Jingzhou Central Hospital
RECRUITING

Jingzhou, Hubei, 434020, China
Jinhua Municipal Central Hospital
RECRUITING

Jinhua, Zhejiang, 321000, China
Jining No.1 People'S Hospital
NOT_YET_RECRUITING

Jining, Shandong, 272011, China
Nantong Cancer Hospital
NOT_YET_RECRUITING

Nantong, Jiangsu, 215004, China
Peking University Third Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100191, China
Puyang Oilfield General Hospital
NOT_YET_RECRUITING

Puyang, Henan, 457001, China
Qilu Hospital Dezhou Branch of Shandong University (Dezhou People's Hospital)
RECRUITING

Dezhou, Shandong, 253000, China
Qingdao Municipal Hospital
NOT_YET_RECRUITING

Qingdao, Shandong, 266000, China
Shenyang Seventh People's Hospital (Shenyang Hospital of Integrated Traditional Chinese and Western Medicine, Shenyang Dermatology Hospital)
WITHDRAWN

Shenyang, Liaoning, 110003, China
Shenzhen Second People's Hospital
RECRUITING

Shenzhen, Guangdong, 518032, China
Shijiazhuang Traditional Chinese Medicine Hospital
NOT_YET_RECRUITING

Shijiazhuang, Hebei, 050000, China
Suining Central Hospital
RECRUITING

Suining, Sichuan, 629000, China
Suzhou Municipal Hospital
RECRUITING

Suzhou, Jiangsu, 215002, China
The First Affiliated Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, 110002, China
The First Affiliated Hospital of Chongqing Medical University 。
NOT_YET_RECRUITING

Chongqing, Chongqing Municipality, 400010, China
The First Affiliated Hospital of Guangxi Medical University
NOT_YET_RECRUITING

Nanning, Guangxi, 530021, China
The First Affiliated Hospital of Kunming Medical University
NOT_YET_RECRUITING

Kunming, Yunnan, 650032, China
The First Affiliated Hospital of Ningbo University
RECRUITING

Ningbo, Zhejiang, 315020, China
The First Peopel's Hospital of Zhengzhou
NOT_YET_RECRUITING

Zhengzhou, Henan, 450004, China
The First People's Hospital of Lianyungang
NOT_YET_RECRUITING

Lianyungang, Jiangsu, 222061, China
The First People's Hospital of Xining
NOT_YET_RECRUITING

Xining, Qinghai, 810000, China
The Second Affiliated Hospital of Henan University of science and technology
NOT_YET_RECRUITING

Luoyang, Henan, 471099, China
The Second Affiliated Hospital of Xi'an Jiaotong University
NOT_YET_RECRUITING

Xi'an, Shaanxi, 710004, China
The Second Hospital of Jilin University
NOT_YET_RECRUITING

Changchun, Jilin, 130000, China
The Second People's Hospital of ChangZhi
NOT_YET_RECRUITING

Changzhi, Shanxi, 46000, China
The Third Xiangya Hospital of Central South University
RECRUITING

Changsha, Hunan, 410013, China
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, 300120, China
Tianjin First Central Hospital
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, 300110, China
Xiangya Hospital of Central South University
NOT_YET_RECRUITING

Changsha, Hunan, 410000, China
Zhengzhou Central Hospital
NOT_YET_RECRUITING

Zhengzhou, Henan, 450000, China
Zhongyi Northeast International Hospital Co., Ltd.
RECRUITING

Shengyang, Liaoning, 110623, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.